BACKGROUND: Bone marrow transplantation (BMT) is associated with bone morbidity. We investigated bone status with quantitative ultrasound (QUS) in pediatric patients with hematological diseases prior to and up to 3 yr following BMT. METHODS: Phalangeal QUS measures for amplitude- dependent speed of sound (Ad-SoS) and bone transmission time (BTT) were obtained in 40 hematological patients (25 with malignant, 15 with non-malignant disease; 9.7+/-4.9 yr) before BMT and 6, 12, 24, and 36 months after BMT. Bone parameters were expressed as Z-scores based on age-sex-matched normal controls. RESULTS: Mean Ad-SoS and BTT Z-scores were normal before BMT and reduced at 36 months (analysis of variance: p=0.0542 and p=0.0233). Ad-SoS and BTT Z-scores remained relatively stable in the first 6 months after BMT and then progressively decreased reaching a plateau at 12-36 months. In non-malignant patients, BTT Z-score decreased at 6-12 months (p=0.029) and subsequently increased, while in malignant patients BTT Z-score showed a decrease at 12-24 months. Pre-pubertal subjects displayed a drop of BTT Z-Score values at both 12 (p=0.023) and 36 months after BMT (p=0.049), while BTT Z-score remained relatively unchanged in pubertal subjects. Early impairment of BTT Z-score was found in patients who suffered acute graft versus host disease (GVHD) compared to patients without this clinical condition; BTT Z-score was lower at 36 months (p=0.045). CONCLUSIONS: Longitudinal assessment by QUS of pediatric BMT survivors evidenced that bone status is mildly affected up to 36 months after BMT, mainly in malignant patients, in pre-pubertal subjects at BMT and in patients who suffered acute GVHD.
BACKGROUND: Bone marrow transplantation (BMT) is associated with bone morbidity. We investigated bone status with quantitative ultrasound (QUS) in pediatric patients with hematological diseases prior to and up to 3 yr following BMT. METHODS: Phalangeal QUS measures for amplitude- dependent speed of sound (Ad-SoS) and bone transmission time (BTT) were obtained in 40 hematological patients (25 with malignant, 15 with non-malignant disease; 9.7+/-4.9 yr) before BMT and 6, 12, 24, and 36 months after BMT. Bone parameters were expressed as Z-scores based on age-sex-matched normal controls. RESULTS: Mean Ad-SoS and BTT Z-scores were normal before BMT and reduced at 36 months (analysis of variance: p=0.0542 and p=0.0233). Ad-SoS and BTT Z-scores remained relatively stable in the first 6 months after BMT and then progressively decreased reaching a plateau at 12-36 months. In non-malignant patients, BTT Z-score decreased at 6-12 months (p=0.029) and subsequently increased, while in malignant patientsBTT Z-score showed a decrease at 12-24 months. Pre-pubertal subjects displayed a drop of BTT Z-Score values at both 12 (p=0.023) and 36 months after BMT (p=0.049), while BTT Z-score remained relatively unchanged in pubertal subjects. Early impairment of BTT Z-score was found in patients who suffered acute graft versus host disease (GVHD) compared to patients without this clinical condition; BTT Z-score was lower at 36 months (p=0.045). CONCLUSIONS: Longitudinal assessment by QUS of pediatric BMT survivors evidenced that bone status is mildly affected up to 36 months after BMT, mainly in malignant patients, in pre-pubertal subjects at BMT and in patients who suffered acute GVHD.
Authors: Giampiero I Baroncelli; Giovanni Federico; Marina Vignolo; Giuliana Valerio; Antonio del Puente; Mohamad Maghnie; Mariangiola Baserga; Giovanni Farello; Giuseppe Saggese Journal: Bone Date: 2006-02-13 Impact factor: 4.398
Authors: J M Stern; K M Sullivan; S M Ott; K Seidel; J C Fink; G Longton; D J Sherrard Journal: Biol Blood Marrow Transplant Date: 2001 Impact factor: 5.742
Authors: G Socié; J Y Cahn; J Carmelo; J P Vernant; J P Jouet; N Ifrah; N Milpied; M Michallet; B Lioure; J L Pico; F Witz; L Molina; A Fischer; V J Bardou; E Gluckman; J Reiffers Journal: Br J Haematol Date: 1997-06 Impact factor: 6.998
Authors: G Socié; R A Clift; D Blaise; A Devergie; O Ringden; P J Martin; M Remberger; H J Deeg; T Ruutu; M Michallet; K M Sullivan; S Chevret Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: K Scott Baker; James G Gurney; Kirsten K Ness; Ravi Bhatia; Stephen J Forman; Liton Francisco; Philip B McGlave; Leslie L Robison; David S Snyder; Daniel J Weisdorf; Smita Bhatia Journal: Blood Date: 2004-06-01 Impact factor: 22.113
Authors: S C Kaste; T J Shidler; X Tong; D K Srivastava; R Rochester; M M Hudson; P D Shearer; G A Hale Journal: Bone Marrow Transplant Date: 2004-02 Impact factor: 5.483
Authors: Lori J Bechard; Catherine Gordon; Henry A Feldman; Robert Venick; Kathleen Gura; Eva C Guinan; Christopher Duggan Journal: Pediatr Blood Cancer Date: 2015-01-28 Impact factor: 3.167